TheProfitWatch

ZNTL - Zentalis Pharmaceuticals, Inc. Common Stock

Day 1m 10m 60m PreMarket Market AfterHours Gap
1.3 0.05 (3.85%) 0.01 (0.37%) 0.01 (0.37%) 0.01 (0.75%) --- 0.05 (3.85%) --- ---

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Category: PHARMACEUTICAL PREPARATIONS
Market Period: Market

Earnings & Ratios

Basic EPS:
-0.37
Diluted EPS:
-0.37
Basic P/E:
-3.6486
Diluted P/E:
-3.6486
RSI(14) 1m:
66.67
VWAP:
1.35
RVol:

Events

Period Kind Movement Occurred At

Related News